WWW.DISSERTATION.XLIBX.INFO
FREE ELECTRONIC LIBRARY - Dissertations, online materials
 
<< HOME
CONTACTS



Pages:     | 1 |   ...   | 4 | 5 || 7 | 8 |   ...   | 9 |

«Suicidality and Antidepressant Drugs Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in ...»

-- [ Page 6 ] --

Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenesis Venlafaxine was given by oral gavage to mice for 18 months at doses up to 120 mg/kg per day, which was 1.7 times the maximum recommended human dose on a mg/m2 basis. Venlafaxine was also given to rats by oral gavage for 24 months at doses up to 120 mg/kg per day. In rats receiving the 120 mg/kg dose, plasma concentrations of venlafaxine at necropsy were 1 times (male rats) and 6 times (female rats) the plasma concentrations of patients receiving the maximum recommended human dose. Plasma levels of the O-desmethyl metabolite were lower in rats than in patients receiving the maximum recommended dose. Tumors were not increased by venlafaxine treatment in mice or rats.

Mutagenesis Venlafaxine and the major human metabolite, O-desmethylvenlafaxine (ODV), were not mutagenic in the Ames reverse mutation assay in Salmonella bacteria or the Chinese hamster ovary/HGPRT mammalian cell forward gene mutation assay. Venlafaxine was also not mutagenic or clastogenic in the in vitro BALB/c-3T3 mouse cell transformation assay, the sister chromatid exchange assay in cultured Chinese hamster ovary cells, or in the in vivo chromosomal aberration assay in rat bone marrow. ODV was not clastogenic in the in vitro Chinese hamster ovary cell chromosomal aberration assay, but elicited a clastogenic response in the in vivo chromosomal aberration assay in rat bone marrow.

Impairment of Fertility Reproduction and fertility studies of venlafaxine in rats showed no adverse effects on male or female fertility at oral doses of up to 2 times the maximum recommended human dose of 225 mg/day on a mg/m2 basis.

25 Reference ID: 3537473 However, reduced fertility was observed in a study in which male and female rats were treated with O-desmethylvenlafaxine (ODV), the major human metabolite of venlafaxine, prior to and during mating and gestation. This occurred at an ODV exposure (AUC) approximately 2 to 3 times that associated with a human venlafaxine dose of 225 mg/day.

Pregnancy Teratogenic Effects - Pregnancy Category C Venlafaxine did not cause malformations in offspring of rats or rabbits given doses up to

2.5 times (rat) or 4 times (rabbit) the maximum recommended human daily dose on a mg/m2 basis. However, in rats, there was a decrease in pup weight, an increase in stillborn pups, and an increase in pup deaths during the first 5 days of lactation, when dosing began during pregnancy and continued until weaning. The cause of these deaths is not known. These effects occurred at 2.5 times (mg/m2) the maximum human daily dose. The no effect dose for rat pup mortality was 0.25 times the human dose on a mg/m2 basis. There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

Non-teratogenic Effects Neonates exposed to Effexor XR, other SNRIs (Serotonin and Norepinephrine Reuptake Inhibitors), or SSRIs (Selective Serotonin Reuptake Inhibitors), late in the third trimester have developed complications requiring prolonged hospitalization, respiratory support, and tube feeding. Such complications can arise immediately upon delivery. Reported clinical findings have included respiratory distress, cyanosis, apnea, seizures, temperature instability, feeding difficulty, vomiting, hypoglycemia, hypotonia, hypertonia, hyperreflexia, tremor, jitteriness, irritability, and constant crying. These features are consistent with either a direct toxic effect of SSRIs and SNRIs or, possibly, a drug discontinuation syndrome. It should be noted that, in some cases, the clinical picture is consistent with serotonin syndrome (see PRECAUTIONS-Drug Interactions-CNS-Active Drugs). When treating a pregnant woman with Effexor XR during the third trimester, the physician should carefully consider the potential risks and benefits of treatment (see DOSAGE AND ADMINISTRATION).

Labor and Delivery The effect of venlafaxine on labor and delivery in humans is unknown.

Nursing Mothers Venlafaxine and ODV have been reported to be excreted in human milk. Because of the potential for serious adverse reactions in nursing infants from Effexor XR, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Pediatric Use Safety and effectiveness in the pediatric population have not been established (see BOX WARNING and WARNINGS, Clinical Worsening and Suicide Risk). Two placebo-controlled trials in 766 pediatric patients with MDD and two placebo-controlled trials in 793 pediatric patients with GAD have been conducted with Effexor XR, and the data were not sufficient to support a claim for use in pediatric patients.

26 Reference ID: 3537473 Anyone considering the use of Effexor XR in a child or adolescent must balance the potential risks with the clinical need.

Although no studies have been designed to primarily assess Effexor XR's impact on the growth, development, and maturation of children and adolescents, the studies that have been done suggest that Effexor XR may adversely affect weight and height (see PRECAUTIONS, General, Changes in Height and Changes in Weight). Should the decision be made to treat a pediatric patient with Effexor XR, regular monitoring of weight and height is recommended during treatment, particularly if it is to be continued long term. The safety of Effexor XR treatment for pediatric patients has not been systematically assessed for chronic treatment longer than six months in duration.





In the studies conducted in pediatric patients (ages 6-17), the occurrence of blood pressure and cholesterol increases considered to be clinically relevant in pediatric patients was similar to that observed in adult patients. Consequently, the precautions for adults apply to pediatric patients (see WARNINGS, Sustained Hypertension, and PRECAUTIONS, General, Serum Cholesterol Elevation).

Geriatric Use Approximately 4% (14/357), 6% (77/1381), 1% (10/819), and 2% (16/1001) of Effexor XR-treated patients in placebo-controlled premarketing major depressive disorder, GAD, Social Anxiety Disorder trials, and panic disorder trials, respectively, were 65 years of age or over. Of 2,897 Effexor-treated (immediate release) patients in premarketing phase major depressive disorder studies, 12% (357) were 65 years of age or over. No overall differences in effectiveness or safety were observed between geriatric patients and younger patients, and other reported clinical experience generally has not identified differences in response between the elderly and younger patients. However, greater sensitivity of some older individuals cannot be ruled out. SSRIs and SNRIs, including Effexor XR have been associated with cases of clinically significant hyponatremia in elderly patients, who may be at greater risk for this adverse event (see PRECAUTIONS, Hyponatremia).

The pharmacokinetics of venlafaxine and ODV are not substantially altered in the elderly (see CLINICAL PHARMACOLOGY). No dose adjustment is recommended for the elderly on the basis of age alone, although other clinical circumstances, some of which may be more common in the elderly, such as renal or hepatic impairment, may warrant a dose reduction (see DOSAGE AND ADMINISTRATION).

ADVERSE REACTIONS

The information included in the Adverse Findings Observed in Short-Term, Placebo-Controlled Studies with Effexor XR subsection is based on data from a pool of three 8- and 12-week controlled clinical trials in major depressive disorder (includes two U.S. trials and one European trial), on data up to 8 weeks from a pool of five controlled clinical trials in GAD with Effexor XR®, on data up to 12 weeks from a pool of five controlled clinical trials in Social Anxiety Disorder, and on data up to 12 weeks from a pool of four controlled clinical trials in panic disorder. Information on additional adverse events associated with Effexor XR in the entire development program for the formulation and with Effexor (immediate release) is included 27 Reference ID: 3537473 in the Other Adverse Events Observed During the Premarketing Evaluation of Effexor and Effexor XR subsection (see also WARNINGS and PRECAUTIONS).

Adverse Findings Observed in Short-Term, Placebo-Controlled Studies with Effexor XR Adverse Events Associated with Discontinuation of Treatment Approximately 11% of the 357 patients who received Effexor XR® (venlafaxine hydrochloride) extended-release capsules in placebo-controlled clinical trials for major depressive disorder discontinued treatment due to an adverse experience, compared with 6% of the 285 placebo-treated patients in those studies. Approximately 18% of the 1381 patients who received Effexor XR capsules in placebo-controlled clinical trials for GAD discontinued treatment due to an adverse experience, compared with 12% of the 555 placebo-treated patients in those studies.

Approximately 15% of the 819 patients who received Effexor XR capsules in placebo-controlled clinical trials for Social Anxiety Disorder discontinued treatment due to an adverse experience, compared with 5% of the 695 placebo-treated patients in those studies. Approximately 7% of the 1,001 patients who received Effexor XR capsules in placebo-controlled clinical trials for panic disorder discontinued treatment due to an adverse experience, compared with 6% of the 662 placebo-treated patients in those studies. The most common events leading to discontinuation and considered to be drug-related (ie, leading to discontinuation in at least 1% of the Effexor XR-treated patients at a rate at least twice that of placebo for any indication) are shown in Table 6.

Table 6 Common Adverse Events Leading to Discontinuation of Treatment in Placebo-Controlled Trials1

–  –  –

28 Reference ID: 3537473 Table 6 Common Adverse Events Leading to Discontinuation of Treatment in Placebo-Controlled Trials1

–  –  –

dose and one was flexible dose. Four of the Social Anxiety Disorder studies were flexible dose and one was fixed/flexible dose.

Two of the panic disorder studies were flexible dose and two were fixed dose.

2 In U.S. placebo-controlled trials for major depressive disorder, the following were also common events leading to discontinuation

and were considered to be drug-related for Effexor XR-treated patients (% Effexor XR [n = 192], % Placebo [n = 202]):

hypertension (1%, 1%); diarrhea (1%, 0%); paresthesia (1%, 0%); tremor (1%, 0%); abnormal vision, mostly blurred vision (1%, 0%); and abnormal, mostly delayed, ejaculation (1%, 0%).

3 In two short-term U.S. placebo-controlled trials for GAD, the following were also common events leading to discontinuation and were considered to be drug-related for Effexor XR-treated patients (% Effexor XR [n = 476]), % Placebo [n = 201]: headache (4%, 1%); vasodilatation (1%, 0%); anorexia (2%, 1%); dizziness (4%, 1%); thinking abnormal (1%, 0%); and abnormal vision (1%, 0%).

4 In long-term placebo-controlled trials for GAD, the following was also a common event leading to discontinuation and was considered to be drug-related for Effexor XR-treated patients (% Effexor XR [n = 535], % Placebo [n = 257]): decreased libido (1%, 0%).

5 In a 6-month placebo-controlled trial for Social Anxiety Disorder, the following was also a common event leading to discontinuation and was considered to be drug-related for Effexor XR-treated patients (% Effexor XR [n = 257], % Placebo [n = 129]: depression (5%, 0%), libido decrease (1%, 0%), and nervousness (3%, 0%).

–  –  –

Adverse Events Occurring at an Incidence of 2% or More Among Effexor XR-Treated Patients Tables 7, 8, 9, and 10 enumerate the incidence, rounded to the nearest percent, of treatmentemergent adverse events that occurred during acute therapy of major depressive disorder (up to 12 weeks; dose range of 75 to 225 mg/day), of GAD (up to 8 weeks; dose range of

37.5 to 225 mg/day), of Social Anxiety Disorder (up to 12 weeks; dose range of 29 Reference ID: 3537473 75 to 225 mg/day), and of panic disorder (up to 12 weeks; dose range of 37.5 to 225 mg/day), respectively, in 2% or more of patients treated with Effexor XR (venlafaxine hydrochloride) where the incidence in patients treated with Effexor XR was greater than the incidence for the respective placebo-treated patients. The table shows the percentage of patients in each group who had at least one episode of an event at some time during their treatment. Reported adverse events were classified using a standard COSTART-based Dictionary terminology.

The prescriber should be aware that these figures cannot be used to predict the incidence of side effects in the course of usual medical practice where patient characteristics and other factors differ from those which prevailed in the clinical trials. Similarly, the cited frequencies cannot be compared with figures obtained from other clinical investigations involving different treatments, uses and investigators. The cited figures, however, do provide the prescribing physician with some basis for estimating the relative contribution of drug and nondrug factors to the side effect incidence rate in the population studied.

Commonly Observed Adverse Events from Tables 7, 8, 9, and 10:

Major Depressive Disorder Note in particular the following adverse events that occurred in at least 5% of the Effexor XR patients and at a rate at least twice that of the placebo group for all placebo-controlled trials for the major depressive disorder indication (Table 7): Abnormal ejaculation, gastrointestinal complaints (nausea, dry mouth, and anorexia), CNS complaints (dizziness, somnolence, and abnormal dreams), and sweating. In the two U.S. placebo-controlled trials, the following additional events occurred in at least 5% of Effexor XR-treated patients (n = 192) and at a rate at least twice that of the placebo group: Abnormalities of sexual function (impotence in men, anorgasmia in women, and libido decreased), gastrointestinal complaints (constipation and flatulence), CNS complaints (insomnia, nervousness, and tremor), problems of special senses (abnormal vision), cardiovascular effects (hypertension and vasodilatation), and yawning.



Pages:     | 1 |   ...   | 4 | 5 || 7 | 8 |   ...   | 9 |


Similar works:

«100 YEARS I'm 15 for a moment Caught in between 10 and 20 And I'm just dreaming Counting the ways to where you are I'm 22 for a moment She feels better than ever And we're on fire Making our way back from Mars 15 there's still time for you Time to buy and time to lose 15, there's never a wish better than this When you only got 100 years to live I'm 33 for a moment Still the man, but you see I'm a they A kid on the way A family on my mind I'm 45 for a moment The sea is high And I'm heading into...»

«References Allerton, D.J. (1982). Valency and the English verb. London: Academic Press. American Psychiatric Association (1994). Diagnostic and statistic manual of mental disorders, 4th Edition (DSM-IV). Washington, DC: American Psychiatric Association. Anderson, S. (1971). On the role of deep structure in semantic interpretation. Foundations of Language, 7, 387-396. Baddeley, A.D. & Hitch, G.J. (1974). Working memory. In: G. Bower (Ed.), The psychology of learning and motivation. New York:...»

«CARLY MCMORRIS, PH.D. PROVISIONALLY REGISTERED PSYCHOLOGIST Calgary, Alberta, Canada Canadian Citizen Telephone: (403) 220-5457 Email: camcmorr@ucalgary.ca CURRENT POSITION Assistant Professor 2016 Werklund School of Education School and Applied Child Psychology Program University of Calgary Office: EDT 508; 2500 University Drive, NW Calgary, Alberta Canada T2N 1N4 Phone: 403-220-5457 EDUCATION Ph.D. in Clinical-Developmental Psychology 2009-2015 York University, Toronto, Ontario Dissertation:...»

«Psychological Explanation, Ontological Commitment, and the Semantic view of Theories Colin Klein 1 Introduction Naturalistic philosophers of mind must assume some philosophy of science. For naturalism demands that we look to psychology—but to be guided by psychological theories, one must have some story about what theories are and how they work. In this way, philosophy of mind was subtly guided by philosophy of science. For the past forty years, mainstream philosophy of mind has implicitly...»

«The Cob Builders Handbook You Can Hand-Sculpt Your Own Home Table Of Contents:  Acknowledgements and Warning INTRODUCTION What is cob? Why build with cob?DESIGNING YOUR HOME SWEET HOME! Things to do to get ready Think Small Think Rounded Make the Most of the Climate Design with passive solar access in mind Other things to think about when designing One Story or More? Noise Plan for Future Additions Now Designing the Entrance Buttresses Permits CHOOSING YOUR SITE Here's a list of some things...»

«Intentional Binding and the Sense of Agency: A review James W. Moore1,2 & Sukhvinder S. Obhi3,4 1. Department of Psychology, Goldsmiths, University of London, London, UK 2. Brain Mapping Unit, Department of Psychiatry, University of Cambridge, Cambridge, UK 3. Centre for Cognitive Neuroscience & Department of Psychology, Wilfrid Laurier University, Waterloo, Ontario, Canada 4. Institute of Cognitive Neuroscience, University College London, London, U.K. Correspondence: sobhi@wlu.ca PrePrint...»

«David Barlow and Panic Disorder 1 RUNNING HEAD: DAVID BARLOW AND PANIC DISORDER The Contribution of David Barlow to the Understanding and Treatment of Panic Disorder Brett J. Deacon, Ph.D.* Tamer I. Fawzy, M.A. University of Wyoming, Laramie, WY University of Wyoming, Department of Psychology, Dept. 3415, 1000 E. University Ave., Laramie, WY 82071, USA *Corresponding author, Tel: 1-307-766-3317, fax 1-307-766-2926 e-mail address: bdeacon@uwyo.edu David Barlow and Panic Disorder 2 The...»

«REWARD AND PUNISHMENT PROCESSING IN SUBGROUPS OF YOUTH WITH CONDUCT PROBLEMS: CHARACTERIZATION OF THE NEURAL RESPONSE AND IMPLICATIONS FOR INTERVENTION by Amy Lynn Byrd, Ph.D. B.S. in Psychology, College of Charleston, 2006 M.S. in Clinical Psychology, University of Pittsburgh, 2010 Submitted to the Graduate Faculty of The Kenneth P. Dietrich School of Arts and Sciences in partial fulfillment of the requirements for the degree of Doctor of Philosophy University of Pittsburgh 2015 UNIVERSITY OF...»

«TECHNISCHE UNIVERSITÄT MÜNCHEN Lehrstuhl für Aquatische Systembiologie Bioindication tools for measuring the success of stream restoration Joachim Wolfgang Pander Vollständiger Abdruck der von der Fakultät Wissenschaftszentrum Weihenstephan für Ernährung, Landnutzung und Umwelt der Technischen Universität München zur Erlangung des akademischen Grades eines Doktors der Naturwissenschaften genehmigten Dissertation. Vorsitzender: Univ.-Prof. Dr. A. Melzer Prüfer der Dissertation: 1....»

«ELYSIUM BOOKS Shortlist 12 ACUN A DE FIGUEROA, Francisco ( attributed). Nomenclatura y apología del carajo. Para la circulaclón [sic] privada. Mon1. tevideo (1922). 14pp. An amusing priapic poem employing numerous synonyms for the word “penis” allegedly written by the nineteenth century Uruguayan poet. $100. AGUIRRE, Luis M. La Lujuria Humana (Estudio Médico-Social). Barcelona: La Vida Literaria (1903?). 95pp. 2. One of a series of pseudo-scientific publications on salacious sexual...»

«A CROSS-CULTURAL STUDY OF THE RELATIONSHIPS BETWEEN EPISTEMOLOGICAL BELIEFS AND MORAL JUDGMENT AS A PSYCHOLOGICAL FOUNDATION FOR MORAL EDUCATION by CHANGWOO JEONG (Under the Direction of RONALD L. VANSICKLE) ABSTRACT Contemporary research has examined relationships between individuals’ epistemological assumptions and their judgments about what is right, fair, and good. However, existing studies primarily have utilized interviews and a questionnaire method with U.S. college students, so less...»

«PHILOSOPHICAL PSYCHOLOGY, VOL. 15, NO. 1, 2002 PANIC theory and the prospects for a representational theory of phenomenal consciousness URIAH KRIEGEL Abstract Michael Tye has recently argued that the phenomenal character of conscious experiences is “one and the same as” (1) Poised (2) Abstract (3) Non-conceptual (4) Intentional Content (PANIC). Tye argues extensively that PANIC Theory accounts for differences in phenomenal character in representational terms. But another task of a theory of...»





 
<<  HOME   |    CONTACTS
2016 www.dissertation.xlibx.info - Dissertations, online materials

Materials of this site are available for review, all rights belong to their respective owners.
If you do not agree with the fact that your material is placed on this site, please, email us, we will within 1-2 business days delete him.